Holen Sie sich die Stockscreener-App
29.90
1.84%
0.54
Avidity Biosciences Inc Aktie (RNA) Neueste Nachrichten
Avidity Biosciences’ SWOT analysis: innovative RNA firm eyes 3-drug launch by 2027 - Investing.com
Wolfe Research Initiates Coverage on Avidity Biosciences (RNA) with 'Outperform' Rating | RNA Stock News - GuruFocus
Avidity Biosciences (RNA) Receives Outperform Rating Amid Biotec - GuruFocus
Why Avidity Biosciences Shares Are Under the Spotlight - TipRanks
Wolfe Research Initiates Coverage on Avidity Biosciences With Outperform Rating, $55 Price Target - MarketScreener
Avidity Biosciences (RNA) Receives Outperform Rating Amid Biotech Advancements | RNA Stock News - GuruFocus
(RNA) Proactive Strategies - news.stocktradersdaily.com
Avidity Biosciences (RNA) Receives Outperform Rating from Wolfe Research | RNA Stock News - GuruFocus
The week in pharma: action, reaction and insight – week to June 13 - The Pharma Letter
Avidity Biosciences’ SWOT analysis: innovative RNA tech targets rare disease stock potential - Investing.com Australia
Avidity Biosciences’ SWOT analysis: innovative RNA tech targets rare disease stock potential By Investing.com - Investing.com South Africa
Avidity Biosciences chief scientific officer sells $657,694 in stock - Investing.com Australia
Avidity Biosciences, Inc. (RNA) Initiated with a Strong Buy at Raymond James - MSN
Avidity Biosciences chief scientific officer sells $657,694 in stock By Investing.com - Investing.com South Africa
13 Biotech Stocks with Huge Upside Potential - Insider Monkey
Avidity Biosciences (RNA) Receives Strong Buy Rating from Raymond James | RNA Stock News - GuruFocus
Avidity Biosciences to Present Topline Data from Phase 1/2 FORTITUDE™ Trial of Del-brax in People Living with Facioscapulohumeral Muscular Dystrophy at 32nd Annual FSHD Society International Research Congress – Company AnnouncementFT.com - Financial Times
Raymond James Initiates Coverage of Avidity Biosciences (RNA) with Strong Buy Recommendation - MSN
Avidity Biosciences holds annual stockholders meeting By Investing.com - Investing.com South Africa
Avidity Biosciences Holds 2025 Annual Stockholder Meeting - TipRanks
Avidity Biosciences holds annual stockholders meeting - Investing.com
Avidity Biosciences price target raised to $75 from $65 at Chardan - Yahoo Finance
JP Morgan Raises Price Target for Avidity Biosciences (RNA) to $59 | RNA Stock News - GuruFocus
The Analyst Verdict: Avidity Biosciences In The Eyes Of 12 Experts - Nasdaq
Avidity Biosciences (RNA) Sees Price Target Increase Amid Promis - GuruFocus
Avidity Biosciences (RNA) Gains Boost with New Price Target and Accelerated Approval Path | RNA Stock News - GuruFocus
Barclays Raises Target Price for Avidity Biosciences (RNA) | RNA Stock News - GuruFocus
Avidity Biosciences (RNA) Price Target Raised Amid Positive Deve - GuruFocus
RNA: Avidity Biosciences Maintains Buy Rating with Price Target Increase | RNA Stock News - GuruFocus
Avidity reports promising FSHD therapy trial results By Investing.com - Investing.com South Africa
Avidity Biosciences Announces the Accelerated Approval Regulatory Pathway in the U.S. is Open for Del-Brax and Initiates the Global, Confirmatory Phase 3 FORWARD™ Study in FSHD - StreetInsider
Avidity Biosciences (RNA) Seeks Accelerated Approval for Key Drug | RNA Stock News - GuruFocus
Avidity Biosciences stock falls following positive trial data By Investing.com - Investing.com Canada
Avidity Biosciences stock falls following positive trial data - Investing.com
BofA lifts Avidity Biosciences stock target to $54 By Investing.com - Investing.com Canada
Avidity Biosciences Touts Encouraging Functional Gains And Biomarker Reductions In Rare Muscular Weakness Disease Trial - Yahoo
Avidity Biosciences (RNA) Price Target Raised Amid Positive Developments | RNA Stock News - GuruFocus
Avidity Biosciences (RNA) Receives Enhanced Price Target Followi - GuruFocus
Transcript : Avidity Biosciences, Inc.Shareholder/Analyst Call - MarketScreener
Avidity Biosciences (RNA) Receives Enhanced Price Target Following Trial Results | RNA Stock News - GuruFocus
Avidity Biosciences Shares Face Turbulence Amid Mixed Signals - TipRanks
Avidity Biosciences (RNA) Reports Promising Results from FSHD Treatment Study | RNA Stock News - GuruFocus
Avidity Biosciences (RNA) Advances Del-brax Approval Pathway for FSHD Treatment | RNA Stock News - GuruFocus
Avidity Reports Positive Phase 1/2 Data For Del-Brax In FSHD Patients - MarketScreener
Avidity reports promising FSHD therapy trial results - Investing.com
Breakthrough FSHD Drug Trial Success: First-Ever Treatment Shows Multiple Improvements in Muscle Disease - Stock Titan
Avidity Biosciences Announces the Accelerated Approval Regulatory Pathway in the U.S. is Open for Del-Brax and Initiates the Global, Confirmatory Phase 3 FORWARD™ Study in FSHD – Company Announcement - Financial Times
Stocks Flashing Renewed Technical Strength: Avidity Biosciences - Investor's Business Daily
(RNA) Investment Analysis - news.stocktradersdaily.com
Avidity Biosciences’ SWOT analysis: innovative muscle therapy stock faces hurdles - Investing.com Nigeria
Myotonic Dystrophy Market to Expand Significantly by 2034, - openPR.com
(RNA) On The My Stocks Page - news.stocktradersdaily.com
Avidity Biosciences Announces Inducement Grants Under Nasdaq Lis - GuruFocus
0.34%
7.69%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):